Welcure Drugs

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 28-Jun, Welcure Drugs & Pharmaceuticals Ltd is experiencing a stock price decline to 0.26, down 3.7%. This is due to significant underperformance against the Sensex, declining investor participation, and trading below key moving averages.

As of 28-Jun, Welcure Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 0.26, which reflects a change of -0.01 or -3.7%. This downward movement can be attributed to several factors. <BR><BR>Firstly, the stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of -7.14% against the Sensex's -0.40%. Over the past month, the stock has decreased by -10.34%, while the Sensex has gained +0.80%. Year-to-date, the stock has fallen by -38.10%, compared to a -9.53% decline in the Sensex. This trend continues over a longer horizon, with a staggering -79.87% drop over the past year, while the Sensex has only decreased by -6.83%.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. There is also a notable decline in investor participation, with delivery volume on June 24 falling by -60.4% compared to the 5-day average. This suggests a lack of interest from investors, further contributing to the stock's decline.<BR><BR>Overall, the combination of poor performance relative to the market, declining investor participation, and trading below key moving averages are key factors leading to the falling stock price of Welcure Drugs & Pharmaceuticals Ltd.

Which are the latest news on Welcure Drugs?

Who are in the management team of Welcure Drugs?

The management team of Welcure Drugs includes D C Jain (Non-Executive Director), Sudhir Chandra (Managing Director), Mitashi Bisaria (Director & Company Secretary), Gagan Juneja (Independent Director), Mohd. Shahbaz Alam (Independent Director), Sitaben S Patel (Additional Director), and Rajeev Mehra (Additional Director).

The management team of Welcure Drugs includes the following individuals:<BR><BR>1. **D C Jain** - Non-Executive & Non-Independent Director<BR>2. **Sudhir Chandra** - Managing Director<BR>3. **Mitashi Bisaria** - Director & Company Secretary<BR>4. **Gagan Juneja** - Non-Executive & Independent Director<BR>5. **Mohd. Shahbaz Alam** - Independent Director<BR>6. **Sitaben S Patel** - Additional Director<BR>7. **Rajeev Mehra** - Additional Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Welcure Drugs?

Welcure Drugs' peers include Lasa Supergeneri, Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Venmax Drugs. Welcure Drugs has average management risk, good capital structure, and a 1-year return of -74.75%, better than Murae Organisor but worse than ANG Lifesciences.

Peers: The peers of Welcure Drugs are Lasa Supergeneri, Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Venmax Drugs.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lasa Supergeneri, Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Venmax Drugs, while Average management risk is found at Welcure Drugs. Growth is Excellent at Roopa Industries, Good at Murae Organisor and Medi Caps, and Below Average at Lasa Supergeneri, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, Venmax Drugs, and Welcure Drugs. Capital Structure is Good at Welcure Drugs, Medi Caps, and Shree Ganesh Bio, Average at Lasa Supergeneri, and Below Average at Murae Organisor, Roopa Industries, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., and Venmax Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ANG Lifesciences at -7.18%, while the peer with the lowest is Murae Organisor at -83.76%. Welcure Drugs has a 1-year return of -74.75%, which is better than Murae Organisor but worse than ANG Lifesciences. Additionally, the six-month returns are negative for Lasa Supergeneri, Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Venmax Drugs.

What does Welcure Drugs do?

Welcure Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1992, with a recent net profit of -50 Cr for March 2026 and a market cap of INR 33 Cr. Key metrics include a P/E of 1.00 and a return on equity of 36.50%.

Overview:<BR>Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited was promoted by D C Jain, Sanjeev Jain, and Sandeep Jain. The latest quarterly results reported a net profit of -50 Cr for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -50 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 33 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 1.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.01<BR>Return on Equity: 36.50%<BR>Price to Book: 0.34<BR><BR>Contact Details:<BR>Address: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034<BR>Phone: 91-011-2701 1428<BR>Email: investor.welcure@gmail.com<BR>Website: https://welcuredrugs.com

Should I buy, sell or hold Welcure Drugs & Pharmaceuticals Ltd?

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

Welcure Drugs & Pharmaceuticals Ltd's latest results are concerning, showing a 100% decline in net sales to ₹0.00 and an operating margin drop to 0.0%. The reported net profit of ₹1.07 crores was misleading, driven entirely by non-operating income, indicating serious operational distress and risks to future viability.

The latest results for Welcure Drugs & Pharmaceuticals Ltd are concerning and indicate significant operational distress. In Q3 FY26, the company reported net sales of ₹0.00, marking a dramatic 100% decline from the previous quarter. This is alarming as it suggests a complete cessation of commercial operations. <BR><BR>While the company reported a net profit of ₹1.07 crores, this figure is misleading as it was primarily driven by other income of ₹1.46 crores, which accounted for over 100% of the profit before tax. The core pharmaceutical business did not contribute to profitability, indicating serious issues with its operational viability.<BR><BR>The operating margin has also dropped to 0.0%, down from 17.31% in the previous quarter, highlighting a severe decline in operational performance. The return on equity (ROE) of 33.54% appears high but is not reflective of sustainable business operations, given the lack of revenue generation.<BR><BR>Overall, the results suggest a troubling situation for Welcure Drugs, with significant risks regarding its future viability and operational continuity. Investors should approach this stock with caution, as the combination of zero revenue and reliance on non-operating income raises serious red flags about the company's financial health.

How has been the historical performance of Welcure Drugs?

Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.

Answer:<BR>The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from previous years where sales were non-existent. The total operating income also rose to 24.55 crore, reflecting the same trend. The company's total expenditure, excluding depreciation, was recorded at 23.67 crore, which is a substantial increase from 0.23 crore in March 2024. Operating profit (PBDIT) for March 2025 was 2.79 crore, a recovery from a loss of 0.14 crore in the previous year. Profit before tax reached 2.78 crore, compared to a loss of 0.17 crore in March 2024, leading to a profit after tax of 2.17 crore, up from a loss of 0.17 crore. The earnings per share (EPS) improved to 0.02 from a negative 0.13 in the prior year, indicating a positive shift in profitability. The operating profit margin for March 2025 was 3.58%, and the profit after tax margin stood at 8.84%, both reflecting a strong performance compared to the previous years where these metrics were at zero. Overall, the financial results for March 2025 demonstrate a significant turnaround for Welcure Drugs, marking its first year of substantial revenue generation and profitability.

What is the bonus history of Welcure Drugs?

Welcure Drugs has announced a 1:10 bonus issue, with an ex-date and record date set for October 16, 2025. Shareholders will receive 1 additional share for every 10 shares held.

Welcure Drugs has a recent bonus issue history where they announced a 1:10 bonus issue. The ex-date for this bonus is set for October 16, 2025. This means that for every 10 shares held, shareholders will receive 1 additional share as a bonus. The record date for this bonus is also October 16, 2025. If you have any more questions about Welcure Drugs or need further details, feel free to ask!

Is Welcure Drugs overvalued or undervalued?

As of September 15, 2025, Welcure Drugs is considered an attractive investment due to its low PE ratio of 3.41 and significant undervaluation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -28.11%.

As of 15 September 2025, the valuation grade for Welcure Drugs has moved from very attractive to attractive. The company is currently considered undervalued, given its low PE ratio of 3.41, a price-to-book value of 0.92, and an EV to EBITDA of 6.45. These ratios indicate that the stock is trading at a significant discount compared to its earnings and book value.<BR><BR>In comparison to its peers, Welcure Drugs stands out with a much lower PE ratio than Sun Pharma (33.52) and Divi's Lab (69.55), both of which are classified as expensive. Additionally, its PEG ratio of 0.01 further emphasizes its undervaluation relative to the industry. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -28.11% compared to the Sensex's 4.67%, the fundamental metrics suggest that Welcure Drugs presents a compelling investment opportunity at its current price.

When is the next results date for Welcure Drugs?

Welcure Drugs will announce its results on 05 August 2025.

Welcure Drugs will declare its results on 05 August 2025.

How big is Welcure Drugs?

As of 24th July, Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, classifying it as a Micro Cap, with recent net sales of 46.64 Cr and net profit of 4.40 Cr over the latest four quarters. Data for shareholder's funds and total assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 46.64 Cr, while the sum of Net Profit for the same period is 4.40 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

Who are the top shareholders of the Welcure Drugs?

The top shareholders of Welcure Drugs are primarily individual investors, holding 98.99% of the shares, with Rahul Ratansingh Sikarwar being the largest individual shareholder at 9.78%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Welcure Drugs primarily consist of individual investors, who hold a significant 98.99% of the company's shares. Among public shareholders, the highest individual shareholder is Rahul Ratansingh Sikarwar, with a holding of 9.78%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Welcure Drugs?

As of May 8, 2025, Welcure Drugs shows a bullish technical trend supported by strong MACD, Bollinger Bands, and moving averages, though caution is advised due to a mildly bullish weekly Dow Theory trend.

As of 8 May 2025, the technical trend for Welcure Drugs has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, indicating strong momentum. Bollinger Bands also reflect a bullish stance on both time frames. Daily moving averages are bullish, supporting the upward trend. The KST is bullish on both weekly and monthly charts, further confirming the positive outlook. However, the Dow Theory shows a mildly bullish trend on the weekly but no trend on the monthly, suggesting some caution. Overall, the current technical stance is bullish with strong indicators supporting this view.

Has Welcure Drugs declared dividend?

No Dividend History Available